Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Glenmark-Celon Can Launch Gx Seretide Accuhaler In Certain Markets • Source: Shutterstock
Glenmark Pharmaceuticals Ltd.’s Europe operations reported a dull third quarter but the firm expects a pick up in the business going forward, aided in part by a settlement pertaining to Salmex (fluticasone/salmeterol), its partnered generic version of GlaxoSmithKline PLC’s Seretide Accuhaler dry powder inhaler.
Glenmark said that the settlement agreement concluded with GSK will allow it and Polish partner Celon Pharma SA to...
Keep up with the top pharma business news of the week. On the go.
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.